Consensus $3.89. Raises FY24 revenue view to up 10%-12% from 8%-10%, consensus $1.27B. Cuts FY24 free cash flow to $160M-$180M from $170M-$190M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HAE:
- Haemonetics 3rd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
- HAE Earnings this Week: How Will it Perform?
- Haemonetics Corporation Completes Acquisition of OpSens Inc.
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
Questions or Comments about the article? Write to editor@tipranks.com